Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LYB001 Immunogenicity and Safety in Adults
NCT05663086Phase 2Withdrawn
- Sponsor
- Patronus Biotech
- Start
- Jan 2023
- Primary completion
- Jun 2023
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant sars-cov-2 vaccine (cho cell) lyb001 in coronavirus disease 2019 (COVID-19), sponsored by Patronus Biotech. Planned start Jan 2023; status: withdrawn.
02
Drugs
recombinant sars-cov-2 vaccine (cho cell) lyb001
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05663086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05663086.